MaaT013 Pooled Fecal Microbiotherapy Improves Gastrointestinal Physiology And Controls Inflammation Which Delays GvHD In A Proof-Of-Concept Humanized Mouse Study
Date : 19/11/2025
Poster à venir !
Previous Post13 novembre 2025 : MaaT Pharma lance une augmentation de capital d’un montant d’environ 9 millions d’euros
Next PostMaaT034, a new co-cultured microbiome ecosystem therapy candidate, potentiates anti-PD1 mediated antitumoral activity in germ-free mice